中國生物製藥(01177.HK)首季純利增118.5%至19.14億元 每股派息2港仙
格隆匯5月24日丨中國生物製藥(01177.HK)公吿,截至2021年3月31日止三個月,集團收入約為72.43億元(人民幣,下同),較去年同期增長約16.4%;毛利約為58.27億元,同比增長約17.6%;歸屬於母公司持有者應占盈利約19.14億元,較去年同期增長約118.5%;歸屬於母公司持有者的每股基本盈利約10.19分,較去年同期增長約118.7%。派發股息每股2港仙。於2021年3月31日,集團的現金及銀行結餘約79.32億元。
期內,新產品銷售收入達到約34.34億元,較去年同期上升約67.0%,佔集團總收入約47.3%;抗腫瘤用藥銷售額約26.38億元,較去年同期上升約31.8%,佔集團收入約36.4%;肝病用藥售額約9.46億元,佔集團收入13.1%;心腦血管用藥銷售額約7.49億元,佔集團收入約10.4%。
集團繼續專注肝病、抗腫瘤、呼吸系統和心腦血管等治療領域的新產品研發。於第一季度內,集團獲得臨牀批件7件、生產批件7件及一致性評價獲批12個、申報臨牀8件、一致性評價申報4個及申報生產2個。已累計有臨牀批件、正在進行臨牀試驗和申報生產的在研產品共393件,其中肝病用藥39件、抗腫瘤用藥185件、呼吸系統用藥25件、內分泌用藥17件、心腦血管用藥16件及其它類用藥111件。
一直以來,集團十分重視研發,以結合自主創新、聯合開發及創仿開發的研發理念,不斷提升研發水平和速度,並視其為可持續發展的基礎,加大研發的資金投入。截至2021年3月31日止三個月,研發總開支約10.62億元,佔集團收入約14.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.